Answers are grounded in this paper and cite their sources.
Poly-ADP ribose polymerase inhibitors (PARPi) have emerged as an important therapeutic option for metastatic castration-resistant prostate cancer, particularly in patients with homologous recombination repair gene alterations such as BRCA1/2 mutations. This comprehensive review examines the biological mechanisms and pharmacological properties of PARPi, analyzes the results of pivotal clinical trials that led to FDA approval for both monotherapy and combination approaches, and explores ongoing investigations of PARPi across the disease spectrum, including metastatic castration-sensitive, biochemically recurrent, and localized prostate cancer.
No takes yet. Share an insight, caveat, or question.
Ababneh et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: